Friday, November 6

08:20–08:35  Welcome

SESSION I – Hodgkin’s Disease
Chairs: Anas Younes (New York) and Andreas Engert (Cologne)

08:35-08:55  Diagnostics
The boundaries of Hodgkin Lymphoma (case-based lecture)  Stefano Pileri (Milan)
08:55-09:00  Discussion

09:00-09:20  First line Treatment
Early stages (case-based lecture)  Marc André (Namur, Yvoir)
09:20-09:25  Discussion

09:25-09:45  First line Treatment
Intermediate/Advanced stages (case-based lecture)  Andreas Engert (Cologne)
09:45-09:50  Discussion

09:50-10:10  Relapsed Disease (case-based lecture)  Anas Younes (New York)
10:10-10:15  Discussion

10:15-10:45  Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)

10:45-11:15  Coffee Break and Poster Viewing

11:15-12:05  DEBATE I: Is there still a role for combined modality therapy for early stage cHL?
Chair: Marc André (Namur, Yvoir)

Audience votes “pro” or “cons”

11:15-11:35  Pro  Joachim Yahalom (New York)
11:35-11:40  Discussion

11:40-12:00  Con  Peter Johnson (Southampton)
12:00-12:05  Discussion

Audience votes again “pro” or “cons”

12:05-12:50  INTERACTIVE CASES

12:50-14:30  Lunch
13:30-14:30  Possible slot for a satellite symposium

SESSION II – T-cell lymphoma
Chairs: Catherine Thieblemont (Paris) and Pier Luigi Zinzani (Bologne)

14:30-14:50  Diagnostics (case-based lecture)  Philippe Gaulard (Créteil)
14:50-14:55  Discussion

14:55-15:15  First line treatment (case-based lecture)  Owen O’Connor (New York)*
15:15-15:20  Discussion

15:20-15:40  Salvage treatment (case-based lecture)  Pier Luigi Zinzani (Bologne)
15:40-15:45  Discussion

15:45-16:05  How clinical trials and the latest update of the WHO classification are shaping current and future therapies for T-cell lymphoma including the use of stem cell transplant – Towards more subtype-specific approaches?  Francesco d’Amore (Aarhus)
16:05-16:10  Discussion

16:10-17:00  ROUNDTABLE I: Interactive cases
Chair: TBA

16:10-16:30  Title TBA  Ghandi Laurent Damaj (Caen)
16:30-16:35  Discussion

16:35-16:55  Title TBA  Gerald Wulf (Göttingen)*
16:55-17:00  Discussion

17:00-17:30  Coffee break and Poster Viewing

SESSION III – Rare Lymphomas – MZL and WM
Chairs: Catherine Thieblemont (Paris) and Christian Buske (Ulm)

17:30-17:50  Diagnostics (case-based lecture)  Maurilio Ponzoni (Milan)
17:50-17:55  Discussion

17:55-18:15  Waldenström (case-based lecture)  Jorge J. Castillo (Boston)
18:15-18:20  Discussion

18:20-18:40  MZL (case-based lecture)  Emanuele Zucca (Bellinzona)
18:40-18:45  Discussion

18:45-19:10  Panel Discussion

19:10-20:00  ROUNDTABLE II – Interactive cases
Chair: Emanuele Zucca (Bellinzona)

19:10-19:30  Marginal Zone Lymphoma case  Alexander Grunenberg (Ulm)
19:30-19:35  Discussion

19:35-19:55  Title  Izidore S. Lossos (Miami)
19:55-20:00  Discussion
20:00  Get together and poster walks (stand up cocktails and buffet dinner for all)

Saturday, November 7

08:00-09:00  3 Simultaneous Meet the Expert sessions (clinical)
1. Circulating free DNA  Davide Rossi (Bellinzona)
2. Pet scan in lymphoma  Michel Meignan (Créteil)
3. Follicular lymphoma  Gilles Salles (Lyon)

SESSION IV – Follicular Lymphoma
Chairs: Christian Buske (Ulm) and Franck Morschhauser (Lille)*

09:00-09:20  Diagnostics (case-based lecture)  Wolfram Klapper (Kiel)
09:20-09:25  Discussion

09:25-09:45  First line (case-based lecture)  Stefano Luminari (Modena)
09:45-09:50  Discussion

09:50-10:10  Salvage treatment (case-based lecture)  Franck Morschhauser (Lille)*
10:10-10:15  Discussion

10:15-10:45  Coffee Break

10:45-11:05  Challenges in FL – POD24 (case-based lecture)  Emmanuel Bachy (Lyon)
11:05-11:10  Discussion

11:10-12:00  DEBATE II: Can we avoid chemotherapy in FL?
Chair: Gilles Salles (Lyon)

Audience votes “pro” or “cons”

11:10-11:30  Pro  Nathan Fowler (Houston)
11:30-11:35  Discussion

11:35-11:55  Con  Umberto Vitolo (Turin)
11:55-12:00  Discussion

Audience votes “pro” or “cons”

12:00-13:50  Lunch

12:40-13:40  Possible slot for a satellite symposium

SESSION V – MCL
Chairs: Anas Younes (New York) and Olivier Hermine (Paris)

13:50-14:10  Diagnostics (case-based lecture)  Elias Campo (Barcelona)
14:10-14:15  Discussion

14:15-14:35  First line treatment (case-based lecture)  Steven Le Gouill (Nantes)
14:35-14:40  Discussion
14:40-15:00  Salvage (case-based lecture)  Martin H. Dreyling (Munich)
15:00-15:05  Discussion

15:05-15:25  BTK failures (case-based lecture)  Simon Rule (Plymouth)*
15:25-15:30  Discussion

15:30-16:00  Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)

16:00-16:30  Coffee break

16:30-17:20  DEBATE III: Do we still need ASCT in MCL?
Chair: Olivier Hermine (Paris)

Audience votes “pro” or “cons”

16:30-16:50  Pro  Marco Ladetto (Alessandria)
16:50-16:55  Discussion

16:55-17:15  Con  Michael Wang (Houston)
17:15-17:20  Discussion

Audience votes “pro” or “cons”

17:20-17:55  INTERACTIVE CASES

18:05-19:05  2 Simultaneous Meet the Expert Sessions (Clinical):
2.  Artificial intelligence for the diagnosis on lymphoma  Camille Laurent (Toulouse)

free evening

Sunday, November 8

SESSION VI – DLBCL
Chairs: Anas Younes (New York) and Catherine Thieblemont (Paris)

08:00-08:20  Diagnostics (case-based lecture)  Ahmet Dogan (New York)
08:20-08:25  Discussion

08:25-08:45  First line (case-based lecture)  Andy Davies (Southampton)
08:45-08:50  Discussion

08:50-09:10  Relapse (case-based lecture)  Jason Westin (Houston)
09:10-09:15  Discussion

09:15-09:35  CAR – T cells (case-based lecture)  Stephen Schuster (Philadelphia)
09:35-09:40  Discussion

09:40-10:10  Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)

10:10-10:30  Coffee break
10:30-11:15  **Key Note Lecture: Biology and New Targets in DLBCL**  Riccardo Dalla Favera (New York)
11:15-11:20  *Discussion*

**SESSION VII – Novel therapeutic concepts in B – cell lymphomas**  
Chair: Corinne Haioun (Créteil)

11:20-11:40  Biomarker-Driven Mechanism-Based Combinations  (case-based lecture)  Anas Younes (New York)
11:40-11:45  *Discussion*

11:45-12:05  Next generation CAR-T cells (case-based lecture)  Michel Sadelain (New York)*
12:05-12:10  *Discussion*

12:10-12:30  Checkpoint Inhibitors and bispecifics (case-based lecture)  Philippe Armand (Boston)*
12:30-12:35  *Discussion*

12:35-13:05  *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

**13:05-13:10  Closing Remarks**

**MEETING CLOSURE**

* To be confirmed